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Abstract. Mapping is a prerequisite for effective implementation of interventions against neglected tropical diseases
(NTDs). Before the accelerated World Health Organization (WHO)/Regional Office for Africa (AFRO) NTD Mapping Project
was initiated in 2014, mapping efforts in many countries were frequently carried out in an ad hoc and nonstandardized
fashion. In 2013, therewere at least 2,200 different districts (of the 4,851 districts in theWHOAfrican region) that still required
mapping, and in many of these districts, more than one disease needed to be mapped. During its 3-year duration from
January2014 through theendof2016, theprojectcarriedoutmappingsurveys foroneormoreNTDs inat least2,500districts
in 37 African countries. At the end of 2016, most (90%) of the 4,851 districts had completed the WHO-required mapping
surveys for the five targeted Preventive Chemotherapy (PC)-NTDs, and the impact of this accelerated WHO/AFRO NTD
Mapping Project proved to be much greater than just the detailed mapping results themselves. Indeed, the AFROMapping
Project dramatically energized and empowered national NTD programs, attracted donor support for expanding these
programs, and developed both a robust NTD mapping database and data portal. By clarifying the prevalence and burden
ofNTDs, theproject providednot only themetrics and technical framework forguidingand trackingprogram implementation
and success but also the research opportunities for developing improved diagnostic and epidemiologic sampling tools for
all 5 PC-NTDs—lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, and trachoma.
INTRODUCTION
Mapping is an essential element for each of the neglected
tropical disease (NTD) programs advocated by the WHO. It
consists of the epidemiological surveys that provide baseline
information on a disease’s geographical distribution, the level of
disease endemicity, and the populations or age-groups in need
of preventive chemotherapy (PC)—all of which information is
critical for planning, implementing, monitoring, and evaluating
NTDprograms.1,2 Indeed, theappropriate targetingofmassdrug
distribution (MDA) requires anunderstandingof thegeographical
distribution of NTDs sufficient to identify those areas that need
the MDA interventions and those that do not, based on WHO
guidelines. Without such data, prioritization of treatment initia-
tives must default to expert opinion or outdated observations
collected historically—potentially leading not only to under-
treatment of needy populations but also to treatment in areas
where treatment is not required and, thus, towastageof donated
medicines, time, and other precious resources.
As early as 2005, the WHO began to categorize a group of
diseases as “NTDs”3 and to reorganize its offices in Geneva
at that time to create a department targeting the NTDs. For
approaching theseNTDs, the concept of “geographicmapping
for prevalence” was first expanded to “geographic mapping
for action”; that is, identifying not just where the diseases are
found but also the specific programmatic treatment or imple-
mentation actions that were required to target each area where
oneormoreNTDsarepresent.4,5 In theWHOAfrican region, the
challenge of “action mapping” for the NTDs was especially
formidable. First, the region comprised a population of nearly
one billion people in 47 countries spread over a vast
geographical area.6 Second, “actionmapping” required that for
each of the NTDs that needed to be action-mapped, defined
program targets or strategies must exist to which specific ac-
tions could be linked—actions determined partly by the dis-
ease’s pre-intervention, baseline prevalence, and partly by the
prior activities undertaken by the programs themselves.7
Between 2005 and 2012, progress of these mapping efforts
was steady but slow. Then came the London Declaration on
NTDs8 in 2012. At that event, the WHO, other international
agencies, donor pharmaceutical companies, the Bill & Melinda
Gates Foundation (BMGF), international and national non-gov-
ernmental organizations (NGOs), and key bilateral development
agencies all pledged to accelerate efforts targeting NTD elimi-
nation or high-level control. For each of these concerned part-
ners, “action mapping” became an urgent priority. It was
this opportune moment of enhanced public- and private-sector
attention that enabled an accelerated, expanded “WHO/AFRO
NTD Mapping Project” to be created: a 3-year project between
late 2013 and 2016 that dramatically transformed the national
NTD programs of the African region.
MATERIALS AND METHODS
Mapping standards and tools. Before the WHO/AFRO
Accelerated NTD Mapping Project was initiated in late 2013,
mapping efforts had been carried out in many countries, but
often in an ad hoc, non-standardized manner with data re-
siding in a variety of locations. The accelerated mapping
project, therefore, established standards and guidelines re-
quired for these NTD mapping surveys; specifically, agree-
ment that 1) the targeted focus for this mapping would be the
district or “admin 3” (which also usually serves as an “imple-
mentation unit” [IU] for NTD programs, defining those areas
where decisions to determine programmatic treatment [or not]
would be made), 2) use would be made of the WHO-agreed,
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standardized mapping methods to identify the prevalence of
eachof the fivePC-NTDs in every district of every country, and
3) data would be collected and accessible centrally. Although
additional, more refined assessments might later be required
for specific programmatic needs9 or to address the known
limitations of existing diagnostic tools in low-prevalence set-
tings, and the principal goal of the accelerated mapping
project was to ensure that PC-NTD endemicity status would
be defined broadly for every district in AFRO’s 47 countries.
For lymphatic filariasis (LF), schistosomiasis (SCH), and soil-
transmitted helminthiasis (STH), the mapping implementation
followed published WHO guidelines and objectives7,10,11 and
was carried out by technical teamsof national programworkers
guided by regional and international consultants, including
members of the WHO/AFRO’s NTD Expert Committee (the
Regional Programme Review Group). Funding support came
principally from the BMGF, national ministries of health, the
international development agencies (the U.S. Agency for In-
ternational Development [USAID] and the UK Department for
International Development [DfID]), and numerous NGOs. The
mapping teams were trained by expert consultants appointed
by bothWHO–AFROand theNTD-Support Center (NTD-SC) at
the Task Force for Global Health.
For onchocerciasis, because mapping had traditionally
been the responsibility of the Onchocerciasis Control Pro-
gramme (1974–2002) and African Programme for Onchocer-
ciasis Control (APOC, 1996–2015), WHO/AFRO allocated a
specific portion of the mapping project funds to APOC to
complete “standard” onchocerciasis mapping9 where still
necessary.
For trachoma, separate funds, principally from the DfID and
USAID, were used to create the Global Trachoma Mapping
Project10 that took responsibility for trachoma mapping in
Africa during the same period when the accelerated WHO/
AFRO NTD Mapping Project was active.
Implementation strategy. The overall strategy of the
acceleratedmapping project was, first, to determine themapping
gaps by collecting all historical information available on PC-NTD
distribution and prevalence in the African Region and then to
support large-scale programmatic implementation of needed
mapping surveys using the most effective tools and approaches
available to capture and record the data. The director of the
mapping project (in Brazzaville) was supported by a regional NTD
mapping coordinator and subregional NTD programmanagers in
eachof theWest,Central,andEast/SouthAfricasubregions,along
with a datamanager and two administrative personnel. This team,
with input fromregional andglobal experts,designedandoversaw
all planning for the implementation of the mapping activities.
Given the complexities of this challenge—first, the different
numbers of different diseases needing to be mapped in dif-
ferent districts in different countries; second, the fact that
unmapped districts had remained unmapped largely because
of their remoteness, minimal infrastructure, conflict, and in-
security; third, the requirement for specific epidemiologic
tools, diagnostics, and expertise to be available at each
mapping site for the prevalence of the PC-NTDs to be de-
termined accurately—this whole exercise presented a truly
enormous organizational and logistical challenge. In total, al-
most 200 individuals were trained in the mapping itself, with
another 50 individuals acting in various supervisory roles and
literally hundreds of supporting field-workers. A further col-
laboration between WHO/AFRO and the NTD-SC at the Task
Force for Global Health assisted with both technical man-
agement and provision of diagnostic tests, ancillary supplies,
data management, and logistics efforts.
Data capture and management. The first activity of the
accelerated NTD mapping project was to take stock of the
available PC-NTD prevalence data still scattered in databases
kept by WHO/AFRO, WHO/Geneva, APOC, national pro-
grams, and NGOs. The available data were categorized as
being sourced from: 1) records of reported endemicity—that
is, areas where the specific NTDs had been known or thought
to be prevalent and where, on that basis, MDA treatment had
already been initiated; 2) available survey data from earlier,
actual mapping surveys—recorded in a variety of ways that
still needed tobeharmonizedandcollated; and3) newsurveys
conducted during the life of the mapping project itself.
These three different kinds of data varied not only as to their
source but also in the level and granularity at which they were
collected, including district, subdistrict, village, site, specific
population, and diagnostic tool. Decision rules were estab-
lished on how to weight or prioritize related data to create
accurate and updated datasets in each country and to decide
how best to use the disparate data to determine which areas
needed no further mapping and which remained as “gaps”
that would require further attention.
TheWHO/AFRONTDdatabase used for this studywasbuilt
on earlier efforts to standardize the capture of mapping data
using digital tools and a small number of linked databases to
manage this information.12 The database had initially been
developed with data fields that recorded district, site, GPS
coordinates, number of people tested, age-groups, number of
positives, specific NTD, and diagnostic methods, and it had
three main levels:
1. an individual (village)-level database
2. an aggregated table, with site-level (subdistrict) data either
already available from the countries or aggregated sub-
sequently from their individual-level data
3. a normalized table of data aggregated at the IU (district)
level—important because for every district, the presenceor
absence of each PC-NTD needed to be defined because
most NTD interventions are implemented at the district
level
At the beginning of the accelerated mapping project, data
aggregated at the site level were requested from the national
programs, and these were then compiled into a master file of
IU (district)-level data. Subsequently, as individual-level data
became available, it was aggregated to site-level data that
then replaced the initial site-level data, after approval by the
countries.
For all mapping survey data acquired during the mapping
project, standardized individual data collection forms were
used to capture the information required to classify each IU
according to WHO endemicity categories and their treatment
implications. In addition, all targeted countries were offered
the use of an electronic data collection tool (LINKS).13 For
reasons of time constraints or concerns about the use of
cloud-based tools, only 16 countries in the WHO/AFRO NTD
Mapping Project used this tool; the other countries opted for
paper-based, standardized data collection forms.
After its collection, the mapping data were shared by na-
tional programs with the WHO regional data managers who
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performed completeness and consistency checks. These
datamanagers supported and liaised closely with the national
programs to ensure that standard data formatswere used and
that data were complete, clean, and internally consistent. All
mapping data were housed andmaintained in the database at
WHO/AFRO headquarters in Brazzaville. An interactive portal
was initiated with dashboards designed to provide data ac-
cess to countries and stakeholders that included themapping
results, treatment activities, and progress toward the control
and elimination of the NTDs. It was this NTD Mapping Portal
that subsequently became the basis of the Expanded Special
Program for Elimination of NTD (ESPEN) Portal (see in the
following text).
RESULTS
Defining the neglected tropical disease “mapping gap.”
At the start of the acceleratedmappingproject, the enormity of
this PC-NTD mapping challenge can be seen in the data of
Table 1.Whereas the numbers of districts in each country (and
their geographic boundaries) can change over time, still na-
tional program managers were able to identify, both from
historical and more recently acquired data, which of their
districts in 2013 were endemic for each of the 5 PC-NTDs and
which still required mapping (i.e., had a “mapping gap”). In
many of the districts, more than one disease needed to be
mapped, but there were at least 2,200 different districts—of
the 4,851 districts in WHO/AFRO in 2013—where mapping
would be required.
Based on the 2013 estimates of mapping needs (Table 1),
AFRO’s 47 countries were grouped into six categories
according to their perceived mapping needs—one group of
countries where standard mapping for the PC-NTDs was
thought to be complete already, based on the compiled
historical data, and five “streams” of countries at different
stages of preparedness for PC-NTD mapping (Figure 1).
Then, what followed during the 3 years of the accelerated
mapping project (2014–2016) was the progressive roll-out of
a large-scale mobilization involving six principal mapping
survey teams organized from the WHO/AFRO offices in
Ouagadougou, Libreville, Harare, and Brazzaville. These
teams were responsible for planning, training, and deploying
technical supervisory teams and national recruits to carry out
WHO-standardized mapping surveys for the PC-NTDs in 28
different countries.
Shrinking the gap—Identifying country-specific preva-
lence of PC-NTDs in Africa. After the initial activities to
organize national data that were already available, the map-
ping teams set out to face the mapping-gap challenges
identified in the data of Table 1 and Figure 1. Using the agreed
tools and strategies during the 3 years from the beginning of
the acceleratedNTDmappingproject in January 2014 through
its end in 2016, the teams carried outmapping for one ormore
PC-NTDs through almost 6,000 individual surveys in 37 Afri-
can countries (Table 2) that included a minimum of 2,500 dif-
ferent districts. Despite discovering somedistricts as endemic
for PC-NTDs that had not been recognized as such in the
earlier “baseline” evaluations of Table 1, still, by the end of
2016, the WHO-required mapping for the targeted NTDs was
complete in all but a few hundred of WHO/AFRO’s 4,851
districts (Figure 2), with more than half of these remaining
districts being in just three partially mapped countries. Details
of these country-specificNTDprevalence results—bothmaps
and district-level data—can be found in AFRO’s ESPEN
Mapping Portal (http://espen.afro.who.int/countries).
DISCUSSION
The impact of the work of AFRO’s accelerated NTD Map-
ping Project was very broad, including:
1. defining PC-NTD disease prevalence in the African region
2. energizing the national NTD programs
3. strengthening national capacity for disease mapping and
implementation
4. stimulating operational research for critical tools and
strategies for national NTD programs
5. ensuring national ownership of epidemiologic data in co-
ordination with the WHO
6. laying the groundwork for subsequent creation of AFRO’s
ESPEN
Preventive Chemotherapy-neglected tropical disease
prevalence. The remarkable progress in PC-NTD mapping
during the 3-year life of the accelerated AFRO–NTD Mapping
Project can be appreciated in both Figure 2 and the data
found online in AFRO’s ESPEN Mapping Portal (http://
espen.afro.who.int/countries). Two principal reasons ac-
count for this success: 1) the effectiveness of the mapping
project in its close individual working relationship with each
country in the African region and 2) the genuinely collaborative
public–private partnership supporting the project. The com-
prehensiveness and standardization of the project’s mapping
strategy, data collection, and data management required nu-
merous technical meetings where national program man-
agers, regional and international consultants, andWHO/AFRO
technical staff all met to examine and organize the available
datasets—one country at a time. Although an intensive, la-
borious undertaking, this effort proved to be an essential in-
vestment in establishing the framework for the rest of the
mapping project and a key to its success. Similarly, the
comprehensiveness of the project’s goal to define the scope
of PC-NTDs in the African region encouraged a broad part-
nership among donors who recognized the opportunities to
support individual mapping initiatives that would be comple-
mentary to each other, ensuring that the result would be a
TABLE 1
Recognized baseline mapping gaps—Pre-mapping project
AFRO Lymphatic filariasis Oncho Schistosomiasis Soil-transmitted helminthiasis Trachoma
No. countries with disease-specific
mapping gap
18 13 27 27 26
No. districts with disease-specific
mapping gap
662 398 981 1,077 1,718
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practical framework underlying the very broad goal of NTD
control and elimination in Africa.
Energizing national NTD programs. In the years leading
up to 2014, most African countries had been encouraged and
supported by WHO/AFRO to create comprehensive national
5-year Master Plans for their NTD programs.14 All of these
plans called for “mapping” each of the PC-NTDs, and, indeed,
much of the rest of the master plan activity depended on the
results of this mapping to target needed program imple-
mentation. Without resources to carry out the necessary
mapping, progress against the NTDs was often stymied, or
at least severely constrained. It was fortunate, therefore, that
FIGURE 1. Streams of countries with their mapping needs. Stream 0 (13 countries), stream 1 (10 countries), stream 2 (15 countries), stream 3
(three countries), stream 4 (four countries), and stream 5 (three countries).
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because of the decision by the BMGF to invest in stimulating
an accelerated WHO/AFRO NTD Mapping Project, funds be-
cameavailable that allowedmanyof theproposed, but stalled,
master plan activities to be jump-started quickly.
Although it is easy to appreciate how such funding would
directly stimulate the mapping and master plan activities,
there was another—probably equally important—conse-
quence. The very engagement of the BMGF in investing to
support an accelerated, comprehensive AfricanNTDmapping
initiative leveraged an almost equivalent amount of funding
from other donors as well, thereby ensuring both that the
mapping could be completed for all five PC-NTDs and that the
WHO/AFRO’s entire program targeting the NTDs would be
significantly energized.
National neglected tropical disease capacity building.
Implementation of the WHO-standardized mapping began
with field training for national survey teams recruited by the
NTD programs to conduct the necessary surveys. These
surveyors were generally laboratory technicians (tasked to
carry out the diagnostic test or procedure), nurses (tasked to
TABLE 2
Countries mapped for different NTDs during the AFRO mapping project
NTD Lymphatic filariasis Soil-transmitted helminthiasis Schistosomiasis Oncho Trachoma
Countries Botswana Angola Angola Angola Benin
Chad Benin Benin Chad Burundi
Congo Botswana Botswana Congo Cameroon
Cote d’Ivoire Burundi Burundi Côte d’Ivoire CAR
DRC Chad Chad DRC Chad
Eritrea Côte d’Ivoire Côte d’Ivoire Eq. Guinea Congo
Ethiopia DRC DRC Ethiopia DRC
Eq. Guinea Eritrea Eritrea Gabon Eritrea
Gabon Ethiopia Ethiopia Nigeria Ethiopia
Madagascar Gabon Gabon Tanzania Gabon
Mauritania Gambia The Gambia Gambia
Niger Guinea Guinea Guinea
Sao Tome and Principe Kenya Kenya Kenya
South Sudan Lesotho Lesotho Malawi
Zimbabwe Liberia Liberia Mozambique
Madagascar Madagascar Nigeria
Mauritania Mauritania Senegal




South Africa South Africa Zimbabwe
South Sudan South Sudan
Swaziland Swaziland
Zimbabwe Zimbabwe
# with at least 1 NTD mapped
37 15 25 25 10 22
DRC = Democratic Republic of the Congo; NTD = neglected tropical disease.
FIGURE 2. District mapping progress by neglected tropical diseases (2014–2016).
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draw blood), andmedical doctors (as supervisors). Before the
fieldwork, technical training was conducted to review the
survey site, population to be tested, sample collected, di-
agnostic used, test interpretation, and method/platform for
data collection and recording. Newdiagnostic tools (e.g., CCA
for SCH) or strategies (e.g., “confirmatory mapping” for LF)
were given special attention during the training. As a result of
their engagement in the accelerated NTD Mapping Project,
these trainees now constitute a pool of technically skilled re-
sources that countries can use for the program assessments
and epidemiologic analyses so essential for both their NTD
and other public health initiatives.
Operational research to refine mapping tools and
strategies. The WHO/AFRO’s accelerated NTD Mapping
Project, in addition to definingwhere and inwhatmeasure PC-
NTDs could be found in 37 countries, also provided unique
opportunities to evaluate newly developed diagnostic tools
andmapping strategies. Indeed, at least 25 of the 37 countries
in the mapping project participated in this operational re-
search. Most of the studies compared operationalization of
newer and older diagnostic tools—for SCH, onchocerciasis,
STH, and LF—but some also tested strategies for integrated
mapping approaches and for confirmation of earlier mapping
results.15 In addition, even after the mapping project ended,
numerous research studies (both mapping- and diagnostics-
related) based on this mapping project work have been initi-
ated, including important studies focused on elimination
mapping for onchocerciasis,9 and the still-unresolved, most
effective diagnostic algorithms to safely treat onchocerciasis
in areas co-endemic with loiasis.16
Preparing for the future—ESPEN: The Expanded Spe-
cial Program for Elimination of NTDs.At the close in 2015 of
the 20-year-old APOC program that oversaw national on-
chocerciasis control and other NTD activities in Africa, a new
organization, ESPEN,was formed in 2016 to fill APOC’s earlier
roles and to consolidate the WHO/AFRO NTD initiatives. In
2016, because the infrastructure initially developed for the
accelerated mapping project was so relevant to the needs of
this new program, critical components necessary for the new
program were immediately available, including
1. personnel skilled in the epidemiologic assessment of NTDs
2. a roster of consultants (mostly national experts) available to
deploy to countries in Africa to collate available mapping
data, identify remaining mapping gaps, and plan and im-
plement surveys where necessary—all using uniform,
standardized techniques
3. technical partners to ensure quality and standardization
across surveys
4. training materials, field manuals, and SOPs—all reflecting
the newest diagnostic tools and insightful strategies for
conducting epidemiologic and mapping surveys
5. established supply chain processes for diagnostics and
ancillary reagents and supplies
Of particular value to the ESPENwas themapping project’s
database and portal, which was transferred and built rapidly
into an ESPEN portal that was live online only a few months
after the ESPEN was established in 2016. That portal (http://
espen.afro.who.int/countries) has provided the first WHO
subnational-level repository of data and cartographyof disease
endemicity and treatment activities. Forty-three countries soon
agreed to make their countries’ data publicly available, and,
indeed, by 2019, this portal had become the go-to site for Af-
rican data on the NTDs—with more than 4,000 maps and cor-
responding datasets openly available to the public. In 2019
alone, 9,255 users visited the portal from 153 countries during
19,362 sessions. The ESPEN has continued working with the
former staff of the WHO/AFRO NTD Mapping Project and its
partners to ensure a continuity of data management built not
only on a consolidation of the collected data but also, espe-
cially, on the trusted relationships that themapping project had
established with the national NTD programs.
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